骨质疏松性肌少症与老年TAVR患者死亡率的关系
该研究为FRAILTY-AVR前瞻性多中心队列的事后分析,纳入605例70岁以上接受TAVR的患者,利用术前CT测量腰大肌面积和椎体骨密度定义骨质疏松性肌少症。结果显示,骨质疏松性肌少症与1年全因死亡率独立相关(OR 3.18,95%CI 1.54-6.57),并可用于识别高风险衰弱患者。
要点
- 骨质疏松性肌少症在TAVR患者中占15%,与衰弱、骨折和营养不良相关。
- 骨质疏松性肌少症独立增加1年死亡风险约3倍,而单纯低骨密度或低肌肉量无此关联。
- 利用临床CT机会性评估骨质疏松性肌少症有助于风险分层和康复干预。
核心结论
- 骨质疏松性肌少症是TAVR术后1年死亡的独立危险因素,风险增加约3倍。
- 该关联在调整衰弱工具和老年综合征后仍持续存在。
研究设计与样本
- FRAILTY-AVR前瞻性多中心队列研究及其McGill扩展的事后分析。
- 纳入2012至2022年间14个中心(加拿大、美国、法国)年龄≥70岁接受TAVR的患者605例。
- 骨质疏松性肌少症通过术前CT测量的腰大肌面积和椎体骨密度按已发表界值定义。
主要发现
- 1年死亡率在骨质疏松性肌少症组为32%(29例),单纯低腰大肌面积组14%(18例),单纯低骨密度组11%(16例),正常组9%(21例)(P < .001)。
- 骨质疏松性肌少症与1年死亡率独立相关(OR 3.18;95% CI 1.54-6.57),并与1年致残恶化独立相关(OR 2.11;95% CI 1.19-3.74)。
- 单纯低骨密度或低腰大肌面积与1年死亡率无独立关联。
关键数值与推荐
- 骨质疏松性肌少症定义为低腰大肌面积合并低椎体骨密度(依据已发表界值)。
- 男性平均腰大肌面积22.1(4.5)cm²,女性15.4(3.5)cm²;男性平均椎体骨密度104.8(35.5)HU,女性98.8(34.1)HU。
临床怎么用
- 对接受TAVR的老年患者,可利用术前CT机会性评估骨质疏松性肌少症以改善风险预测。
- 识别骨质疏松性肌少症可支持治疗决策并触发康复干预。
局限性
- 本研究为事后分析,可能存在残余混杂。
- 骨质疏松性肌少症的定义基于已发表界值,未在文中重新验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Osteosarcopenia is an emerging geriatric syndrome characterized by age-related deterioration in muscle and bone. Despite the established relevance of frailty and sarcopenia among older adults undergoing transcatheter aortic valve replacement (TAVR), osteosarcopenia has yet to be investigated in this setting. OBJECTIVE: To determine the association between osteosarcopenia and adverse outcomes following TAVR. DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc analysis of the Frailty in Aortic Valve Replacement (FRAILTY-AVR) prospective multicenter cohort study and McGill extension that enrolled patients aged 70 years or older undergoing TAVR from 2012 through 2022. FRAILTY-AVR was conducted at 14 centers in Canada, the United States, and France between 2012 and 2016, and patients at the McGill University-affiliated center in Montreal, Québec, Canada, were enrolled on an ongoing basis up to 2022. EXPOSURE: Osteosarcopenia as measured on computed tomography (CT) scans prior to TAVR. MAIN OUTCOMES AND MEASURES: Clinically indicated CT scans acquired prior to TAVR were analyzed to quantify psoas muscle area (PMA) and vertebral bone density (VBD). Osteosarcopenia was defined as a combination of low PMA and low VBD according to published cutoffs. The primary outcome was 1-year all-cause mortality. Secondary outcomes were 30-day mortality, hospital length of stay, disposition, and worsening disability. Multivariable logistic regression was used to adjust for potential confounders. RESULTS: Of the 605 patients (271 [45%] female) in this study, 437 (72%) were octogenarian; the mean (SD) age was 82.6 (6.2) years. Mean (SD) PMA was 22.1 (4.5) cm2 in men and 15.4 (3.5) cm2 in women. Mean (SD) VBD was 104.8 (35.5) Hounsfield units (HU) in men and 98.8 (34.1) HU in women. Ninety-one patients (15%) met the criteria for osteosarcopenia and had higher rates of frailty, fractures, and malnutrition at baseline. One-year mortality was highest in patients with osteosarcopenia (29 patients [32%]) followed by those with low PMA alone (18 patients [14%]), low VBD alone (16 patients [11%]), and normal bone and muscle status (21 patients [9%]) (P < .001). Osteosarcopenia, but not low VBD or PMA alone, was independently associated with 1-year mortality (odds ratio [OR], 3.18; 95% CI, 1.54-6.57) and 1-year worsening disability (OR, 2.11; 95% CI, 1.19-3.74). The association persisted in sensitivity analyses adjusting for the Essential Frailty Toolset, Clinical Frailty Scale, and geriatric conditions such as malnutrition and disability. CONCLUSIONS AND RELEVANCE: The findings suggest that osteosarcopenia detected using clinical CT scans could be used to identify frail patients with a 3-fold increase in 1-year mortality following TAVR. This opportunistic method for osteosarcopenia assessment could be used to improve risk prediction, support decision-making, and trigger rehabilitation interventions in older adults.
引用
- Solla-Suarez P, Arif SG, Ahmad F, et al. Osteosarcopenia and Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiol. 2024. PMID: 38748410. doi:10.1001/jamacardio.2024.0911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。